New York-based neurology specialist Mind Medicine (Nasdaq: MNMD) has announced positive topline results from its Phase IIb clinical trial of MM-120.
Mind Medicine is a clinical stage drug developer working on psychedelic medicines.
MM-120, also known as lysergide d-tartrate, is a classic psychedelic being tested for generalized anxiety disorder (GAD).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze